Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria candidate AK006 following disappointing Phase I trial results. Also, Merck & Co ...
Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).
Sage Therapeutics, Inc. NASDAQ: SAGE) is officially exploring "strategic alternatives" to make shareholders happy. The process includes anything from a possible business combination to a full-on ...
Today, a brief rundown of news involving BioAge Labs and Roche, as well as updates from Akero Therapeutics, Allakos and Vanda Pharmaceuticals that you may have missed. A growing cohort of biotechs, ...
Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following underwhelming Phase I results. This ...
Allakos, based in San Carlos, issued a press release Monday announcing topline results from its phase 1 clinical trial of AK006. AK006 was developed as a form of treatment for chronic spontaneous ...
Investing.com -- Shares of Allakos Inc . (NASDAQ:ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of therapeutic ...
California, USA-based biotech Allakos (Nasdaq: ALLK) saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing top-line results from its Phase I clinical trial of AK006 in ...